Matrixyl

Mechanism of action

Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a synthetic cosmetic peptide developed by Sederma (now part of Croda International) as a topical dermal collagen-synthesis stimulator. The active pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser) is derived from the C-terminal propeptide sequence of the type-I procollagen α1 chain — the small peptide fragment generated when procollagen is processed to mature collagen by procollagen C-endopeptidase. The observation that this natural cleavage product produced feedback stimulation of collagen synthesis in dermal fibroblasts motivated its development as a cosmetic active. The palmitoyl (C16 fatty acid) N-terminal modification is essential for topical utility — the unmodified KTTKS pentapeptide has negligible skin penetration; palmitoylation enables percutaneous absorption through the stratum corneum lipid barrier while retaining the intrinsic collagen-stimulating activity of the pentapeptide. The molecular mechanism involves engagement of dermal fibroblasts and induction of the collagen synthesis programme. Pal-KTTKS increases expression of type-I and type-III collagen, fibronectin, and glycosaminoglycans in cultured human dermal fibroblasts at nanomolar-to-micromolar concentrations. The specific receptor or intracellular target has been incompletely characterised — the mechanism is not the discrete receptor-mediated pharmacology of GHK-Cu at melanocortin-like signalling but rather a broader collagen-programme-inducing effect that may involve TGF-β-related pathway modulation and direct fibroblast transcriptional effects. The effect is dose-dependent and reproducible in cell culture; the effect size at typical cosmetic concentrations is modest but detectable. At the tissue level, topical Matrixyl application produces increased dermal collagen deposition, improved dermal thickness, and reduced wrinkle depth in controlled cosmetic clinical studies. Effect sizes are modest — typically 10-30% improvement on standardised wrinkle-depth measurements over 3-6 months of twice-daily application at 3-4% concentrations (a typical commercial concentration). This is smaller than the effect sizes claimed for tretinoin (retinoic acid, the gold-standard prescription anti-ageing topical) but larger than placebo vehicle in well-controlled studies. The Matrixyl 3000 variant (which combines Pal-GHK and Pal-GQPR, both palmitoylated peptides with distinct mechanisms) is Sederma's second-generation product with modest additional effects. A critical distinction from GHK-Cu is that Matrixyl targets collagen synthesis through a fibroblast-programme-induction mechanism without any copper-delivery or metal-ion pharmacology. GHK-Cu is a copper-tripeptide addressing multiple mechanisms including lysyl oxidase (collagen cross-linking), broad transcriptional modulation, and antioxidant defence. Matrixyl and GHK-Cu are therefore complementary cosmetic actives rather than substitutes — cosmetic formulations sometimes combine them, though the copper reactivity of GHK-Cu requires careful formulation to prevent adverse interactions with reducing agents and other actives. From a research pharmacology standpoint, Matrixyl is fundamentally a cosmetic-grade compound rather than a therapeutic-grade drug candidate. Effect sizes are modest but reproducible; safety is exceptional given the topical use and the fibroblast-targeting mechanism; and the regulatory status as a legal cosmetic ingredient (rather than an unlicensed medicine) makes commercial use straightforward. It does not compete with prescription anti-ageing therapies (tretinoin, laser resurfacing, injectable dermal fillers) but complements them in cosmetic skincare regimens.

Matrixyl (Pal-KTTKS) is derived from the natural type-I procollagen C-terminal propeptide fragment generated during collagen maturation — the peptide that naturally feeds back to stimulate additional fibroblast collagen synthesis. Palmitoylation enables topical delivery of this natural signalling molecule, providing modest but reproducible anti-ageing effects across 25+ years of widespread commercial cosmetic use.

— Notable finding

Research history

Matrixyl (Pal-KTTKS) was developed by Sederma, a French cosmetic-ingredient company that became part of Croda International in 1997. The compound was introduced commercially in 2000 as a novel dermal collagen-stimulating cosmetic ingredient with the marketing positioning of 'peptide skincare' — one of the earliest commercially successful cosmetic peptides. The Sederma medicinal-chemistry rationale started from the collagen propeptide biology: the observation that the natural C-terminal propeptide fragment generated during collagen maturation feeds back to stimulate additional collagen synthesis in fibroblasts. Synthesising a stable, palmitoylated version of the pentapeptide KTTKS enabled topical delivery of this natural signalling molecule. Commercial adoption was rapid across the mid-2000s, with Matrixyl becoming one of the most widely used cosmetic peptide ingredients globally. Commercial products under the L'Oréal, Olay, StriVectin, and numerous other brand umbrellas have incorporated Matrixyl at typical concentrations of 2-8% by weight (with the free peptide-content substantially lower given the complex-formulation architecture). The compound holds INCI listing as Palmitoyl Pentapeptide-4 (or Palmitoyl Pentapeptide-3 in older nomenclature), enabling legal cosmetic use across the EU, UK, US, and most other jurisdictions. Sederma subsequently developed Matrixyl 3000, a second-generation variant combining Pal-GHK (a palmitoylated version of the same tripeptide backbone as GHK-Cu but without copper) with Pal-GQPR. The combination was marketed as producing enhanced effects relative to Pal-KTTKS alone, though the differential efficacy claims are modest. Independent clinical trial data on Matrixyl efficacy have accumulated across the 2000s and 2010s, generally supporting the compound's cosmetic anti-ageing activity in controlled dermatology clinical studies. Effect sizes are modest but reproducible; the safety profile is exceptional for a topical cosmetic active. Matrixyl remains among the most commercially successful cosmetic peptide ingredients as of 2026, with widespread continued use across the anti-ageing skincare product category. The compound's academic and pharmaceutical research interest is limited compared to therapeutic peptides — it operates in the cosmetic-ingredient regulatory space rather than the pharmaceutical space.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Matrixyl has one of the strongest safety records of any compound on this site, reflecting 25+ years of widespread commercial cosmetic use across many millions of consumer exposures. The typical topical adverse-event profile is minimal: rare contact sensitisation (~<1%), occasional mild transient erythema at high concentrations or on sensitive skin, no documented systemic adverse events, no documented endocrine or reproductive concerns. The topical fibroblast-targeting mechanism has essentially no systemic exposure at cosmetic use concentrations. Palmitoylation enables percutaneous absorption to the dermis but the compound does not achieve meaningful systemic circulation. This limits the safety concerns to the local dermal effects, which have proven consistently minimal. Allergic contact dermatitis from Matrixyl-containing products is uncommon; when it occurs it is typically attributable to formulation excipients (preservatives, fragrances) rather than to the peptide active itself. Photosensitivity has not been documented. The compound's pregnancy safety profile is not extensively characterised in formal studies but the topical-cosmetic use case, minimal systemic absorption, and 25+ year commercial use record without documented pregnancy-related concerns provide substantial reassurance. Most cosmetic dermatology guidance considers topical Matrixyl products acceptable during pregnancy and lactation, though patients should follow individual clinician guidance. No serious adverse events have been documented in the extensive commercial use record. The compound's safety record supports the modest but reproducible efficacy — a favourable risk-benefit profile for cosmetic anti-ageing use. The principal 'safety' concern is more accurately framed as a concern about consumer expectations. Cosmetic Matrixyl products produce modest anti-ageing effects; consumer expectations of substantial wrinkle reversal or skin rejuvenation may not be met, leading to consumer disappointment rather than any pharmacological safety issue.

UK regulatory status

Matrixyl (palmitoyl pentapeptide-4) is a legal cosmetic ingredient in the United Kingdom, regulated under the UK Cosmetic Products Regulation (Retained Regulation (EC) 1223/2009 as amended following Brexit). It is INCI-listed as Palmitoyl Pentapeptide-4 (with older Palmitoyl Pentapeptide-3 nomenclature persisting in some regulatory contexts) and can be included in cosmetic formulations without concentration limits, provided the finished cosmetic product meets the general safety obligation and is manufactured to appropriate cosmetic-industry standards. Commercial anti-ageing skincare products containing Matrixyl are widely available in the UK through cosmetic retail channels (pharmacies, department stores, cosmetic-specialist retailers, online). No prescription is required. Typical Matrixyl content is 2-8% by weight in commercial formulations, though the free peptide-active content is substantially lower given the complex formulation architecture. As a topical cosmetic ingredient, Matrixyl is not subject to MHRA medicines regulation. It is not a controlled substance under the Misuse of Drugs Act 1971. It is not on the WADA Prohibited List. Research use of Matrixyl in dermatology, cosmetic-science, and fibroblast-biology research contexts is straightforward — research-grade material is widely available from cosmetic-ingredient suppliers, and possession/use for research purposes is unrestricted. For animal research under ASPA, Matrixyl work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit, though most Matrixyl research uses in-vitro fibroblast culture models rather than in-vivo animal studies. The critical UK regulatory distinction is between cosmetic use (legal, unrestricted) and any hypothetical use as a licensed medicine for anti-ageing dermatology (which would require MHRA authorisation that has not been sought and is not commercially pursued). Cosmetic-ingredient status is the regulatory framework relevant to essentially all Matrixyl use.

Frequently asked questions